PER-ENCOUNTER MEDICAL MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Per-Encounter Medical Market, By Product Type (Consumables, Devices, Software, Services, and Others), By Application (Cardiology, Orthopedics, Obstetrics/Gynecology, Ophthalmology, Gastroenterology, and Others), By Distribution Channel (Direct Tender, Retail Sales, and Online Sales), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Recent Developments:

New product Approvals and launches:

On February 11, 2020, Bluegrass Vascular Technologies, a medical technology company, received a De Novo classification order from the U.S. Food and Drug Administration (FDA) for its Surfacer Inside-Out Access Catheter System. The system is developed to obtain central venous access for catheter insertion into the central venous system for patients with upper body venous occlusions.
On May 5, 2022, Access Vascular, Inc. (AVI), a manufacturing company of biomaterial-based vascular access devices, announced that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its HydroPICC Dual-Lumen catheter. Designed and constructed using the same proprietary hydrophilic biomaterial as AVI’s single-lumen HydroPICC and HydroMID catheters. These devices showed significant reduction in complications such as occlusions, replacements, deep vein thrombosis, and phlebitis in studies.

Agreement and partnerships:

On November 19, 2021, Numedico, a global company in medical technology, signed a global distribution partnership with a medical devices distributor PBC Medicals L.L.C. Numedico. The partnership worth US$ 5.5 million allowed Numedico in distributing their ClickZip Safety Syringe technology into the global markets.
On May 24, 2021, as part of the national response to COVID-19, the Department of Defense (DOD), in coordination with the Department of Health and Human Services (HHS), signed an agreement with Retractable Technologies, Inc. (RTI), a company manufactures safety medical devices with automated retraction has expand the production of the low dead-space (LDS) safety syringes and needles. The government allocated fund worth US$ 27.3 million.